ALX Oncology Holdings Inc.
ALXO
$1.93
-$0.08-3.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.83% | -32.43% | -24.08% | -16.49% | -20.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.16% | -40.40% | -24.80% | -30.81% | -43.47% |
| Operating Income | 22.16% | 40.40% | 24.80% | 30.81% | 43.47% |
| Income Before Tax | 30.74% | 41.71% | 21.65% | 27.89% | 34.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.74% | 41.71% | 21.65% | 27.89% | 34.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.74% | 41.71% | 21.65% | 27.89% | 34.14% |
| EBIT | 22.16% | 40.40% | 24.80% | 30.81% | 43.47% |
| EBITDA | 22.20% | 40.47% | 24.77% | 30.81% | 44.90% |
| EPS Basic | 72.71% | 70.26% | 23.79% | 29.07% | 36.13% |
| Normalized Basic EPS | 70.48% | 70.27% | 23.78% | 29.08% | 43.95% |
| EPS Diluted | 72.71% | 70.26% | 23.79% | 29.07% | 36.13% |
| Normalized Diluted EPS | 70.48% | 70.27% | 23.78% | 29.08% | 43.95% |
| Average Basic Shares Outstanding | 153.79% | 95.98% | 2.80% | 1.68% | 3.11% |
| Average Diluted Shares Outstanding | 153.79% | 95.98% | 2.80% | 1.68% | 3.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |